Cosmetic And Personal Care Weekly Trademarks Review: 26 July
You may also be interested in...
Keeping Track: Enhertu Brings Anti-HER2 Therapy To Lung Cancer; Novaliq Platform Supports Two Dry Eye NDAs
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.
Establishing VMS products MPL as stated within legislation to re-authorize FDA user fee programs for drugs, biologics and medical device applications isn’t urgent enough to prevent passing user fee bill, says CRN chief Steve Mister.
Study finds one-third of insured adults have access to hepatitis C treatment within 360 days of the first positive test. CDC suggests treating all eligible patients without restrictions and eliminating preauthorization requirements. For state Medicaid programs, 38 states require prior authorization and 12 states have substance use restrictions.